 | |
| Clinical data | |
|---|---|
| Other names | 6-MABB; 6-(2-Methylaminobutyl)benzofuran |
| Drug class | Serotonin–norepinephrine–dopamine releasing agent;Entactogen |
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.285 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-MBPB, also known as6-(2-methylaminobutyl)benzofuran (6-MABB), is amonoamine releasing agent (MRA) andentactogen-likedrug of theamphetamine,phenylisobutylamine, andbenzofuran families.[1][2][3][4][5] It is apositional isomer of5-MBPB (5-MABB).[1][2][3][4][5]
The drug appears to act as aserotonin–norepinephrine–dopamine releasing agent (SNDRA).[1][2] TheEC50Tooltip half-maximal effective concentration values for induction of monoamine release in rat brainsynaptosomes have been reported for the individualenantiomers of 6-MBPB.[2] In the case of (S)-6-MBPB, they were 54 nM forserotonin, 77 nM fornorepinephrine, and 41 nM fordopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine.[2] Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is aserotonin–norepinephrine releasing agent (SNRA).[2] The enantiomers showed a mixed profile of acting as full versuspartial releasers.[2] Unlike5-MAPB, it is a relatively weakserotonin5-HT1B receptoragonist.[6] 6-MBPB partially substituted forMDMA in animaldrug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.[1][2][4]
Along with 5-MBPB, 6-MBPB waspatented byMatthew Baggott andTactogen in 2021.[5] It was first described in thescientific literature by 2022.[3][4] 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.[1][2]
Stimulus substitution tests were conducted with (RS) 5-MAPB, (R)-5-MAPB, (S)-5-MAPB, (R)-5-MBPB, (S)-5-MBPB, (R)-6-MBPB, and (S)-6-MBPB. All substances produced full substitution for MDMA. In separate experiments, serotonin release and reuptake assays with rat synaptosomes indicated these substances are substrate releasers of serotonin with nanomolar potency; slightly higher potency was observed with the S-enantiomers. The benzofuran scaffold may allow development of substances that retain MDMA-like therapeutic effects while reducing toxicities associated with MDMA.